193.ppt
DESCRIPTION
TRANSCRIPT
Prognostic value of exercise testing
Paolo PalangeUniversità “La Sapienza” – Roma
PG 12 Cardiopulmonary exercise testing and interpretation
Objectives
To discuss the role of exercise testing the prognostic evaluation of patients with chronic lung and heart diseases
Exercise variables/indexes that have high prognostic value in patients with chronic lung and heart diseases
Gibbons RJ, 2002
Duke Treadmill Score
N Engl J Med 2002
MET “Metabolic Equivalent Term”
1 MET = 3.5 mlO2/min/Kg (3.5x70=245 mlO2/min)
MET = speed x [0.1 + (inclination x 1.8)] + 3.5
3.5
Evaluating the severity/prognosis of patients with chronic pulmonary and
cardiac diseses
FEV1 (CF, COPD)DLco (ILD, PPH)PaO2, PaCO2 (COPD, CF, PPH)BMI (CF, COPD, PPH)Dyspnea (COPD, PF)EF, NYHA (CHF)
100100
8080
6060
4040
2020
00
11 33 44 55 6622
No CHFCHF I
CHF II
CHF III
CHF IV
Time, yrs
Su
rviv
al,
%S
urv
ival,
%Survival rate and NYHA classesSurvival rate and NYHA classes
FEV1 and prognosis in COPD
AJRCCM 2003; 167:544-549AJRCCM 2003; 167:544-549
*
* ATS severity of COPD
B, body mass index
O, obstruction (FEV1)
D, dyspnea (Borg scale) E, exercise (6’WT)
NEJM 2004; 350: 1005-12
The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary
Disease
Exercise limitation in lung diseases
V/Q mismatch Work of breathing VD/VT airflow elastic
PAO2 pH obstruction recoil
ventilatory ventilatory requirement capacity
(K. Wasserman,2004)COPD
Muscle Fatigue
ATPATP LactateLactate V’COV’CO22
Exercise intolerance
Factors that may influence exercise ventilatory response in COPD
1) ventilatory drive (↓pH, ↓pO2)
2) wasted ventilation (↑ VD/VT)
3) ↑ pulmonary vascular resistances
4) metabolic acidosis (↑ CO2 output)5) differences in muscle mass and fiber
types recruited during exercise6) differences in neurogenic afferent
from exercising limbs
Johnson BD, CHEST 1999; 116: 488-503Johnson BD, CHEST 1999; 116: 488-503
Exercise testing in the prognostic evaluation
Exercise variables/indexes that have a high
prognostic value in patients with chronic pulmonary and cardiac diseses
V’O2 peak (COPD, CF, PPH, CHF)V’O2 at LT (CHF)V’E/V’CO2 slope or at LT (CHF)Arterial O2 desaturation (ILD, CF)Dyspnea (COPD, PF)
6’WT distance (CHF, CF, COPD, PH)
Classification of Exercise capacity in patient with CHF
Peak V’O2 ATClass Impairment (mL/kg/min) (mL/kg/min)A None to mild > 20 >14
B Mild to moderate 16-20 11-14
C Moderate to severe 10-16 8-11
D Severe < 10 < 8
Weber et al. Circulation 1987Weber et al. Circulation 1987
Circulation 1991; 83:778-786
V’O2 peak and prognosis in CHF
Circulation 1991; 83:778-786
Time (months)
Peak V’O2 (ml/kg/min)
Kaplan-Meier life-table analysis for V’O2 max > 45% vs < 45% predicted
Kleber FX, Circulation 2000Kleber FX, Circulation 2000
Ventilatory demand in CHF
Kaplan-Meier life-table analysis for V’E/V’CO2 slope <130% vs >130%
predicted
Kleber FX, Circulation 2000Kleber FX, Circulation 2000
Gitt AK, Circulation 2002
Exercise Anaerobic Threshold and Ventilatory Efficiency Identify Heart Failure Patients for
High Risk of Early Death
Gitt AK, Circulation 2002
Exercise Anaerobic Threshold and Ventilatory Efficiency Identify Heart Failure Patients for
High Risk of Early Death
Criterion for Cardiac Transplantation
Category for peak V’O2
Transplant (mL/kg/min)
Accepted indication <10
Probable indication <14
Inadequate indication >15
Mudge et al. J Am Coll Cardiol 1993Mudge et al. J Am Coll Cardiol 1993
JACC 2004:787-93
Patient with Heart Failure
Maximize medical therapy
Heart Failure Survival Score
Medium
Beta-blockers tolerated
Assess Peak VO2 (ml/min/kg)
10-14<10 >14Evaluate for transplant Continue medical therapy
High risk Low riskEvaluate for transplant
Beta-blockers not tolerated
Continue medical therapyReassess in one year
Selection of Patients for Heart Transplantation in the Current Era of Heart Failure Therapy
JACC 2003:2175-81
Periodic Breathing During Incremental Exercise Predicts Mortality in Patients with Chronic Heart Failure Evaluated for Cardiac
Transplantation
In COPD, V’O2 peak predicts mortality independently of FEV1
Oga T, AJRCCM 2003Oga T, AJRCCM 2003
The prognostic value of exercise testing in patients with
CF
Nixon PA, NEJM 1992
100 90 80 70 60 50 40 30 20 10 0
1 2 3 4 5 6 7 8 Year
Su
rviv
al R
ate
(%
)
V’O2 peak < 58% pred. V’O2 peak 59-81% pred.V’O2 peak > 82% pred.
AJRCCM 2002; 165:1629
An Elevated Breathing Reserve Index at the Lactate Threshold is a predictor of Mortality
in Patients with Cystic Fibrosis awaiting Lung Transplantation
Circulation 2002; 106:319-324
Assessment of Survival in Patients with Primary Pulmonary Hypertension
(PPH):Importance of Cardiopulmonary Exercise
Testing
Eur Respir J, Jan 2007
Eur Respir Monograph 2007
Future Directions
“Endurance” protocols
Recovery
Combination of variables